Harbin Gloria Pharmaceuticals (002437) — Strategic Asset Allocation Index
Harbin Gloria Pharmaceuticals (002437) has a Strategic Asset Allocation Index of 58.1% as of September 2023. Strategic assets (PP&E of CN¥1.08 Billion plus long-term investments of CN¥-) total CN¥1.08 Billion, measured against net assets of CN¥1.86 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Harbin Gloria Pharmaceuticals Strategic Asset Allocation Index (2010–2021)
This chart shows how Harbin Gloria Pharmaceuticals's Strategic Asset Allocation Index has evolved across 12 annual periods from 2010 to 2021. As of September 2023, the index stands at 58.1%, representing strategic assets of CN¥1.08 Billion against net assets of CN¥1.86 Billion CNY. Explore Harbin Gloria Pharmaceuticals (002437) cash conversion ratio to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Harbin Gloria Pharmaceuticals (2010–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Harbin Gloria Pharmaceuticals from 2010 to 2021, covering 12 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Harbin Gloria Pharmaceuticals market cap and net worth.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 62.4% | CN¥1.24 Billion | CN¥1.24 Billion | CN¥- | CN¥1.98 Billion | ▼ -6.9 pp |
| 2020 | 69.3% | CN¥1.34 Billion | CN¥1.34 Billion | CN¥- | CN¥1.93 Billion | ▼ -25.2 pp |
| 2019 | 94.5% | CN¥1.50 Billion | CN¥1.50 Billion | CN¥- | CN¥1.59 Billion | ▲ +37.9 pp |
| 2018 | 56.6% | CN¥2.49 Billion | CN¥1.72 Billion | CN¥766.54 Million | CN¥4.39 Billion | ▲ +2.6 pp |
| 2017 | 54.0% | CN¥2.30 Billion | CN¥1.78 Billion | CN¥517.83 Million | CN¥4.25 Billion | ▼ -2.7 pp |
| 2016 | 56.7% | CN¥2.30 Billion | CN¥1.81 Billion | CN¥480.37 Million | CN¥4.05 Billion | ▲ +4.9 pp |
| 2015 | 51.8% | CN¥1.80 Billion | CN¥1.64 Billion | CN¥154.68 Million | CN¥3.47 Billion | ▲ +25.0 pp |
| 2014 | 26.8% | CN¥831.40 Million | CN¥831.40 Million | CN¥- | CN¥3.10 Billion | ▼ -0.2 pp |
| 2013 | 27.0% | CN¥668.68 Million | CN¥668.68 Million | CN¥- | CN¥2.48 Billion | ▲ +3.2 pp |
| 2012 | 23.8% | CN¥560.95 Million | CN¥560.95 Million | CN¥- | CN¥2.36 Billion | ▲ +4.8 pp |
| 2011 | 18.9% | CN¥416.25 Million | CN¥416.25 Million | CN¥- | CN¥2.20 Billion | ▲ +6.4 pp |
| 2010 | 12.6% | CN¥266.93 Million | CN¥266.93 Million | CN¥- | CN¥2.12 Billion | — |